Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
India · Delayed Price · Currency is INR 1,972.00
-58.70 (-2.89%)
Sep 26, 2025, 3:29 PM IST
Glenmark Pharmaceuticals Employees
Glenmark Pharmaceuticals had 15,800 employees as of March 31, 2025. The number of employees increased by 811 or 5.41% compared to the previous year.
Employees
15,800
Change (1Y)
811
Growth (1Y)
5.41%
Revenue / Employee
8.52M INR
Profits / Employee
477.03K INR
Market Cap
556.42B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 15,800 | 811 | 5.41% |
| Mar 31, 2024 | 14,989 | -567 | -3.64% |
| Mar 31, 2023 | 15,556 | 141 | 0.91% |
| Mar 31, 2022 | 15,415 | 4,451 | 40.60% |
| Mar 31, 2021 | 10,964 | 297 | 2.78% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sun Pharmaceutical Industries | 43,000 |
| Divi's Laboratories | 10,542 |
| Cipla | 30,313 |
| Apollo Hospitals Enterprise | 42,497 |
| Mankind Pharma | 26,978 |
| Zydus Lifesciences | 27,917 |
| Fortis Healthcare | 12,237 |
| Alkem Laboratories | 18,785 |
Glenmark Pharmaceuticals News
- 10 days ago - Glenmark Pharma enters licensing pact with Astria; positive early results from STAR-0310 trial: Report - Business Upturn
- 19 days ago - Glenmark Pharma shares jump over 2% after its subsidiary gets $700 million from AbbVie for licensing deal - Business Upturn
- 19 days ago - Glenmark Pharma receives $700 million upfront payment from AbbVie for global licensing deal - Business Upturn
- 23 days ago - Glenmark Pharma initiates multi-country Phase 3 Clinical Trial for Envafolimab in Stage III NSCLC - Business Upturn
- 25 days ago - Bajaj Electricals, UBL& more: Top stocks on brokers' radar today - The Times of India
- 25 days ago - Glenmark Pharma shares jump over 2% as HSBC maintains ‘Buy’ rating with target price of Rs 2,380 - Business Upturn
- 25 days ago - Glenmark Pharma share: HSBC maintains buy with Rs 2,380 target, highlights catalysts in debt reduction and FDA approvals - Business Upturn
- 26 days ago - Stocks to watch on brokerages today, September 3: ITC, Adani Power, Indus Towers, UBL, Glenmark Pharma and more - Business Upturn